ASSESSMENT OF HYDROGEN PEROXIDE GENERATION IN NEUTROPHILS

中性粒细胞中过氧化氢生成的评估

• 批准号: 6289456
• 负责人: thomas a fleisher
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6289456
• 关键词: chronic granulomatous disease; clinical research; flow cytometry; human subject; hydrogen peroxide; leukocyte oxidative burst; method development; neutrophil

Previous work established that the flow cytometric dihydrorhodamine (DHR)-based assay for evaluation of oxidative burst is a sensitive method for evaluating phagocytes in patients with possible chronic granulomatous disease (CGD). It has also been useful as an accurate test for screening possible X-linked CGD carriers and a preliminary screen for the genotype of the disease. The method was optimized and is sensitive to one normal cell in less than or equal to 10,000 abnormal cells. A project was undertaken to track granulocytes post-transfusion in CGD patients following allogeneic leukocyte transfusions and this assay has proven to be very reliable in establishing duration of transfused cell survival and allsensitization. The results of this study were presented at the American Association of Blood Banks annual meeting. The second phase of gene therapy of CGD continues directed at patients with X-linked CGD. The DHR assay is being applied as a critical method for establishing the presence of gene-corrected granulocytes in the circulation and monitoring the duration of production of the gene-corrected cells in the treated patients

先前的研究证实，基于二氢何达明（DHR）的氧化爆发流式细胞测定是一种评估可能患有慢性肉芽肿病（CGD）患者吞噬细胞的灵敏方法。它还可以作为筛选可能的x连锁CGD携带者的准确测试和疾病基因型的初步筛选。该方法经优化后，在少于或等于10,000个异常细胞中对一个正常细胞敏感。研究人员开展了一个项目，跟踪输注同种异体白细胞后的CGD患者输血后的粒细胞，该试验已被证明在确定输注细胞存活时间和全致敏性方面非常可靠。这项研究的结果在美国血库协会年会上公布。CGD基因治疗的第二阶段继续针对x连锁CGD患者。DHR测定是一种关键的方法，用于确定循环中基因校正的粒细胞的存在，并监测治疗患者中基因校正细胞产生的持续时间